IMUX (Immunic) 3-1 Month Momentum %: 48.69% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMUX Immunic Inc IMUX
32 GF Score
Price $15.00
! 3 Warning Signs
View Full Analysis

What is Immunic 3-1 Month Momentum %?

Immunic IMUX -0.97% 32 3-1 Month Momentum % is 48.69% as of Jul. 21, 2026. GuruFocus rates IMUX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,381 Biotechnology companies, Immunic ranks better than 95.51% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-21), Immunic's 3-1 Month Momentum % is 48.69%.

The industry rank for Immunic's 3-1 Month Momentum % or its related term are showing as below:

IMUX's 3-1 Month Momentum % is ranked better than
95.51% of 1381 companies
in the Biotechnology industry
Industry Median: -13.34 vs IMUX: 48.69

Immunic  (NAS:IMUX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Immunic 3-1 Month Momentum % Related Terms

IMUX vs WHWK, ALEC, TTRX: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Immunic's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunic 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Immunic's 3-1 Month Momentum % falls into.


IMUX
32GF Score
Immunic Inc IMUX
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunic  (NAS:IMUX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 48.69% mean?
Immunic (IMUX) has a 3-1 Month Momentum % of 48.69% as of Jul. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Immunic and its competitors. According to the industry distribution chart, Immunic ranks #62 out of 1381 companies in the Biotechnology industry, placing it in the top 4.5%.
Is Immunic's 3-1 Month Momentum % too high?
Immunic's current 3-1 Month Momentum % is 48.69%. Based on the distribution chart, Immunic ranks #62 out of 1381 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunic has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Immunic's 3-1 Month Momentum % compare to WHWK and ALEC?
According to the Biotechnology industry distribution chart, Immunic ranks #62 out of 1381 companies for 3-1 Month Momentum %. This places Immunic in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Immunic and its competitors. Immunic's current 3-1 Month Momentum % is 48.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunic stock overvalued right now?
Immunic (IMUX) has a current 3-1 Month Momentum % of 48.69%. The current 3-1 Month Momentum % is 48.69%. Immunic's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Immunic (IMUX), the current 3-1 Month Momentum % is 48.69% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunic Business Description

Other Exchanges 10V:Germany
Address 1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
32GF Score

Get the complete analysis for IMUX

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.00
Price